Crescent Biopharma (CBIO) is scheduled to report Q1 earnings on May 23, 2026. Analysts estimate EPS of $-0.81 and quarterly revenue of $357.14K.

In the most recent quarter (Q4), Crescent Biopharma reported EPS of $-4.01, missing estimates of $-2.58 by 0.55%. Revenue came in at $10.84M, missing the estimate of $12.50M by 0.13%.

Crescent Biopharma has missed EPS estimates in 3 consecutive quarters.

Over the last 3 quarters, Crescent Biopharma has averaged an EPS surprise of 1.38% and a revenue surprise of 0.13%.